Gastrointestinal Cancer

Bristol Myers Squibb’s CheckMate-577 trial, which evaluated nivolumab to treat patients with resected esophageal or gastroesophageal junction cancer, met the primary end point of disease-free survival.

This study found that smoking was associated with an increased risk of gastric cancer incidence and mortality, while not drinking was correlated with a stronger beneficial effect of garlic supplementation on gastric cancer prevention.

In this multi-institutional study, regorafenib demonstrated modest clinical efficacy in heavily pretreated patients with biliary tract cancer.